|
ApoImmune Finalist for "Best Early-Stage Vaccine Biotech" at World Vaccine Congress ViE Awards
May 1, 2009 (Louisville, KY) - ApoImmune, Inc., a Louisville-based biotechnology company developing vaccines and immunotherapies was selected as a finalist for "Best Early-Stage Vaccine Biotechnology Company" at the recently held World Vaccine Congress in Washington, DC. The Vaccine Industry Excellence (ViE) Awards are an integral part of the annual World Vaccine Congress and recognize the outstanding achievements of vaccine practitioners and stakeholders across the global industry. These awards have been created to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry.
Now in its 9th year, the World Vaccine Congress remains the industry's definitive vaccine industry event for major vaccine players. Officially the longest-running and largest vaccine industry event in North America, the World Vaccine Congress delivers a forum where the ever-changing dynamics of the vaccine industry are discussed and acted upon by the industry's most senior figures.
"Almost 400 attendees from more than 200 companies from around the world attended the World Vaccine Congress this year and we were honored to be selected as a finalist for "Best Early-Stage Vaccine Biotech," said Steven T. Downey, President and CEO of ApoImmune, Inc. "Being chosen for this prominent award demonstrates that the industry recognizes the innovative nature of our technology and its strong commercial potential. We believe that ApoImmune's broad vaccine platform technology and the commercial potential it holds to treat unmet clinical needs in cancer and infectious diseases is now being recognized around the world. We are looking forward to furthering our work and reputation, and hope to accelerate the transition of our technology into the marketplace."
About ApoImmune, Inc.
ApoImmune, Inc. is a Louisville, Kentucky-based biotechnology company developing novel vaccines and immunotherapies, which are treatments based on the concept of regulating the immune system to fight disease. The Company's lead vaccine is ApoVax104-HPV, a therapeutic vaccine for cervical cancer expected to be tested in human clinical trials in late 2009. ApoImmune is also developing a second platform technology which improves current organ and tissue transplant therapies by protecting the transplant from being attacked by the recipient's immune system when transplanted into the body.
For more information, visit www.apoimmune.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
back to Latest News
|
|
|
